November 30, 2021 10:54 AM EST
News Briefing

Sci­wind gets li­cens­ing deal with Sanofi for meta­bol­ic dis­ease can­di­dates; Im­mu­ni­ty­Bio and En­Gene­IC reach deal for nano cell tech

Paul Schloesser

Associate Editor

Sci­wind Bio­sciences an­nounced last night that it signed an ex­pan­sive li­cense agree­ment with Sanofi to de­vel­op and com­mer­cial­ize Sanofi’s long-last­ing glu­cose …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times